How big is the plasma protease C1-inhibitor market?

The global plasma protease C1-inhibitor market size was estimated at USD 3.33 billion in 2023 and is expected to reach USD 3.54 billion in 2024.

What is the plasma protease C1-inhibitor market growth?

The global plasma protease C1-inhibitor market is expected to grow at a compound annual growth rate of 9.79% from 2024 to 2030 to reach USD 6.21 billion by 2030.

Which segment accounted for the largest plasma protease C1-inhibitor market share?

C1-inhibitors dominated the Drug Class segment accounted for the largest share of 53.14% in 2023 and selective bradykinin B2 receptor antagonist anticipated to grow at fastest growth rate over the forecast period owing to undergoing R&D initiatives being undertaken by major players.

Who are the key players in plasma protease C1-inhibitor market?

Market players operating in plasma protease C1-inhibitor market include CSL Behring LLC., Takeda Pharmaceutical Company, Pharming Technologies B.V., KalVista Pharmaceuticals, Inc., Shire plc., CSL Limited, Sanquin, Pharming Group N.V.).